adjust dilut earn per share ep defin report
relat cost discontinu oper certain signific
ep forecast revenu estim full year ep guidanc
ep estim consensu
ep guidanc rais penni vs prior last publish
estim
sale estim
consensu sale build-up reflect prior segment categori product beat
estim includ lipitor eliqui prevnar
celebrex enbrel viagra norvasc lyrica combin
forecast product estim includ xeljanz sutent xtandi
premarin ibranc inlyta xalkori chantix zyvox combin
forecast sale guidanc reiter last publish
revenu estim flat
gpm estim
estim sg estim net non-
oper incom estim tax rate
estim share count estim
event expect includ bavencio approv rcc w/inylta pdufa june
rituxan approv rivipansel ph data sickl cell diseas tafamidi approv
ttr-cardiomyopathi pdufa dmd gene therapi ph data
late june ph data atop dermat consum divis
complet jv gsk complet list event shown follow
pleas see page report import disclosur
outperform rate stock key averag bottom-lin growth
improv innovation/new product flow solid dividend yield compel valuat
share appear under-valued sotp basi
tafamidi approv ttr
cardiomyopathi pdufa juli
bavencio inlyta approv rcc
ph data atop dermat
rivipansel ph data scd
everi earli stage product
launch achiev
pipelin achiev greater expect
accret potenti break-up
compani lead greater valuat
pfizer inc global biopharmaceut compani divers portfolio pharma product
cover area cardiovascular anti-infect anti-inflammatori oncolog
metabol diseas other also strong vaccin portfolio consum product
segment array brand product
cowen compani
changenet expens inc mm cowen
cowen compani
cowen compani
cowen
cowen compani
cowen
cowen compani
cowen compani
cowen compani
time frameev gene terapyphas data first sever patient late june hemophilia gene therapi initi phase ibrancephas pearl data nsai resisti data atop dermatitisrivipanselphas data sickl cell diseas data cv outcom studi cvtrumenbainiti phase yr oldsregulatorybavencio inlytau /eu approv rcc pdufa june biosimilar avastin zirabev approvalbiosimilar humirau /eu approv bsufa rituxanu approv bsufa approv psoriasislorviqua lorlatinib eu/jp approv alk nsclc posit chmp vyndaqel approv ttr-cardiomyopathi pdufa juli novemb file ttr-cardiomyopathytalzenna talazoparib eu approv mbrca bc posit chmp rcv apr file hspccorporateconsum divisioncomplet jv gsk cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock novarti adr roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc act financi advisor inc connect acquisit roch hold ag announc februari
author report member author household long posit equiti secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
